Abstract 1728P
Background
The prevalence of oncology survivors is increasing exponentially. More than half of them experience difficulty in returning to their pre-disease socio-familial role. Comprehensive Oncology Units are infrequent in our environment. In our center we have implemented this novel Unit in order to improve the quality of life of our cancer survivors during follow-up.
Methods
Prospective quasi-experimental study. From March 2022 to March 2023. A total of 232 patients were included in the Comprehensive Oncology Unit of the Juan Ramón Jiménez Hospital in Huelva. The aim of our study is to describe the psychosocial, nutritional and physical needs of cancer survivors during follow-up and the impact of the intervention on their quality of life.
Results
The median age of the patients was 53 years (33 - 78). Ninety-six percent were women. Ninety percent had been diagnosed with breast cancer, followed by 6 % CRC, 2 % other digestive tumors and 2 % gynecological tumors. 67.1% required assessment for nutrition, 62.9% for rehabilitation, 59.28% for psycho-oncology and 4.8% for social intervention. Of the patients who were evaluated by psycho-oncology, 50% improved their fear of recurrence with only 3 sessions. Regarding nutrition assessment, the median BMI in the population with BMI > 25kg/m2 was 30.7 Kg/m2 at baseline and 29.71 Kg/m2 (22.7 - 40) 6 months after nutrition intervention (p<0.001).
Conclusions
The results of our study reveal that there is a high demand of needs to be covered in cancer survivors beyond the purely clinical aspects that impact on their quality of life. Implementing a Comprehensive Oncology Unit could help to detect these needs and improve their healthy lifestyle habits as well as improve their quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Oncology Unit.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2375P - Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Presenter: Zhou Tong
Session: Poster session 23
2376P - Pembrolizumab monotherapy following tri-modality treatment for selected patients with muscle-invasive bladder cancer
Presenter: Shang Bin Qin
Session: Poster session 23
2378P - Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment
Presenter: Vadim Koshkin
Session: Poster session 23
2379P - AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Presenter: Philippe Barthélémy
Session: Poster session 23